Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIB7734 for ALI in COVID-19
NCT04526912Phase 1Terminated
- Sponsor
- Viela Bio
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute lung injury (ALI) comparing VIB7734 Dose with Placebo (2 arms). Primary endpoint: Proportion of patients who achieve treatment success defined as avoidance of death and critical illness at Day 28. Started Aug 2020; status: terminated.
02
Drugs
daxdilimab
03
Conditions
coronavirus disease 2019 (COVID-19)acute lung injury (ALI)
Beyond the preview
Go deeper on NCT04526912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526912.